SMIC 1H26 Net Profit USD677M Up 111%
SMIC FY26 H1 profit attributable to owners more than doubles to USD 676.65 million; revenue rises 23.7% to USD 5.51 billion
BofAS Raises WUXI BIO TP to HKD56 as Backlog Orders Grow
How Investors Are Reacting To BeOne Medicines (ONC) First-Line HER2-Positive GEA Immunotherapy Approval
Analyst Jill Wu Raises Target Price and Reiterates Buy on Innovent Biologics After Strong 1H26 Beat and Robust Growth Outlook
WuXi Biologics: Upgraded Growth Outlook and Higher DCF-Based Target Price Support Buy Rating